A therapy showing promise to help control tuberculosis (TB) does not interfere with combined antiretroviral therapy (cART), according to research by Texas Biomedical Research Institute (Texas Biomed).

Tuberculosis is the infectious disease with the highest death rate worldwide. As reported by WHO, therapy-resistant tuberculosis infections are increasing. Diseases due to this bacterial infection ...

Every year, an estimated 410,000 people worldwide contract a multidrug-resistant form of tuberculosis. During treatment, approximately a quarter of patients experience linezolid-associated adverse ...

Directly observed therapy — where a health professional watches someone take a medication — has been the standard of care for tuberculosis treatment in the United States since 2016.

Treatment of active TB requires at least six months of uninterrupted therapy. Disruptions in treatment result in further spread of TB and the emergence of multidrug resistant TB, which requires ...

New promising tuberculosis therapy shows potential in improving outcomes for HIV-positive patients, offering hope for better treatment and improved health. Indoleamine-2,3-dioxygenase inhibition ...

Cutting-edge tuberculosis therapy: Researchers test quabodepistat combinations, aiming for shorter, safer treatments to combat drug resistance and improve patient outcomes. Study: Safety ...

While some of the TB programs may ultimately survive, none have received any money for months. Family members of infected people are not being put on preventive therapy. Infected adults are ...

The initiation of antiretroviral therapy (ART) after starting TB treatment is complex, involving many variables including treatment tolerance, drug co-toxicities, pharmacokinetic drug interactions ...

The guidelines endorse the use of a three-month course of TB preventive therapy as opposed to the old six-month course. But, while the intention is to roll out the three-month course quite widely ...